Ignite Creation Date:
2024-05-06 @ 3:59 AM
Last Modification Date:
2024-10-26 @ 11:42 AM
Study NCT ID:
NCT02425644
Status:
COMPLETED
Last Update Posted:
2023-01-04
First Post:
2015-04-21
Brief Title:
Oral Ponesimod Versus Teriflunomide In Relapsing MUltiple Sclerosis
Sponsor:
Actelion
Organization:
Actelion
Study Overview
Official Title:
Multicenter Randomized Double-blind Parallel-group Active-controlled Superiority Study to Compare the Efficacy and Safety of Ponesimod to Teriflunomide in Subjects With Relapsing Multiple Sclerosis
Status:
COMPLETED
Status Verified Date:
2023-01
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
OPTIMUM
Brief Summary:
International clinical trial to compare ponesimod and teriflunomide in relapsing multiple sclerosis
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
True
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| 2012-000540-10 | EUDRACT_NUMBER | None | None |